GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Notes Receivable

VGI Health Technology (XNEC:VTL) Notes Receivable : A$0.00 Mil (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Notes Receivable?

VGI Health Technology's Notes Receivable for the quarter that ended in . 20 was A$0.00 Mil.


VGI Health Technology Notes Receivable Historical Data

The historical data trend for VGI Health Technology's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Notes Receivable Chart

VGI Health Technology Annual Data
Trend
Notes Receivable

VGI Health Technology Semi-Annual Data
Notes Receivable

VGI Health Technology Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


VGI Health Technology Notes Receivable Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


VGI Health Technology (XNEC:VTL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines